Durvalumab alone and durvalumab plus tremelimumab versus chemotherapy in previously untreated patients with unresectable, locally advanced or metastatic urothelial carcinoma (DANUBE): a randomised, open-label, multicentre, phase 3 trialVsevolod Matveev, Matthew D. Galsky, Yohann Loriot et al.|The Lancet Oncology|2020Cited by 502